Moreover, we selected the key lncRNA EMX2OS among 4 ccRCC‐related ERLRs and found that EMX2OS might play an important role in the tumor microenvironment through a potential EMX2OS/hsa‐miR‐31‐5p/TLN2 regulatory axis, influencing the survival of patients with ccRCC and potentially guide clinical medication and immunotherapy, thereby providing a clue for precise treatment of ccRCC patients. This evidence concerns the gene EMX2OS and nonpapillary renal cell carcinoma.